Cancer Management and Research (Nov 2019)

Retrospective Analysis Of Comparative Outcomes In Recurrent Platinum-Sensitive Ovarian Cancer Treated With Pegylated Liposomal Doxorubicin (Lipo-Dox) And Carboplatin Versus Paclitaxel And Carboplatin

  • Weng CS,
  • Wu CC,
  • Chen TC,
  • Chen JR,
  • Huang CY,
  • Chang CL

Journal volume & issue
Vol. Volume 11
pp. 9899 – 9905

Abstract

Read online

Chia-Sui Weng,1,* Chao-Chih Wu,2,* Tze-Chien Chen,1 Jen-Ruei Chen,1 Chueh-Yi Huang,1 Chih-Long Chang1–3 1Department of Obstetrics and Gynecology, MacKay Memorial Hospital, Taipei, Taiwan; 2Department of Medical Research, MacKay Memorial Hospital, New Taipei City, Taiwan; 3Department of Medicine, Mackay Medical College, New Taipei City, Taiwan*These authors contributed equally to this workCorrespondence: Chih-Long ChangDepartment of Obstetrics and Gynecology, Mackay Memorial Hospital, 92, Section 2, Chung-Shan North Road, Taipei, TaiwanTel +886-2-25433535 Fax +886-2-25232448Email [email protected]: The aim of this study is to analyze the outcomes of platinum-sensitive (PS) recurrent ovarian cancer treated with pegylated liposomal doxorubicin and carboplatin (CD) versus paclitaxel and carboplatin (CP). Clinical features were examined to characterize the patient population that would benefit from CD.Materials and methods: This is a retrospective review of 122 cases at a tertiary hospital. Patients with PS recurrent ovarian cancer who received CD or CP were included. Progression-free survival (PFS) and overall survival (OS) were evaluated through the Kaplan–Meier method and log-rank test. Cox proportional hazards regression was used to examine PFS predictors.Results: In total, 122 patients (75% with first recurrence and 25% with second recurrence) were included. The majority of the patients were diagnosed at an advanced stage and with the histology of serous carcinoma. Median PFS and OS were 14.8 and 55.5 months in the CD group and 13.5 and 56.8 months in the CP group. Subgroup analysis of patients revealed that the CD group had longer median PFS than the CP group among patients with PFI>12 months. Additionally, during the second recurrence, longer PFS was observed in the CD group than in the CP group (medians 22.3 and 13.5 months, respectively, p = 0.019).Conclusion: Comparable outcomes in recurrent platinum-sensitive ovarian cancer treated with CD versus CP were presented in this study. Longer PFS in CD group was observed among patients with PFI for more than 12 months or in second recurrence.Keywords: Lipo-Dox, platinum-sensitive ovarian cancer  

Keywords